FDA-designated

Cytotron for breast cancer

One of three cancers covered by the Cytotron®'s US FDA Breakthrough Device Designation, granted in October 2019. Breast cancer was also the most common diagnosis in the published 2016 clinical study.

Cytotron® therapy is always planned into the care your oncologist provides, never instead of it. Sessions last about an hour, you lie comfortably, and nothing enters the body.

Send your reports for a free review How RFQMR works

What you should know

Where it fits: Planned into your wider treatment — surgery, systemic therapy, hormone therapy, HER2-targeted treatment — with the order worked out individually. Most of the women we see are partway through systemic therapy or in the maintenance phase after primary treatment.
Who we assess: Anyone with a solid tumour visible on a recent scan, well enough to attend daily sessions, and under the care of a treating oncologist. Your hormone receptor and HER2 status shape the wider programme we build around you.
Your course: Daily sessions over a defined period, with a review scan at a point agreed with you at the start. Length is set from your own imaging — genuinely yours, not a standard package.

Every plan is worked out individually from your own reports. We'll tell you plainly if we don't think Cytotron® therapy will help in your situation.

Ask us about your case

Send your pathology report, most recent scan and treatment summary. A doctor reviews them personally and replies within a working day, free and with no obligation.

Other cancers

Send your reports

Three short steps. A doctor reads your file properly and replies within one working day — no charge, no obligation.

1About you
2The diagnosis
3Your reports

Step 1 of 3 — About you

So we know who we're writing back to.

No charge
Reply in 1 working day
Seen only by our clinicians

Prefer to skip the form? Message us on WhatsApp. For anything urgent, please ring your treating hospital. More ways to reach us.